Tivic Health outlines $20B oncology market opportunity following strategic transformation

Earnings Call Insights: Tivic Health Systems, Inc. (TIVC) Q4 2025

MANAGEMENT VIEW

* Michael Handley, CEO, announced, "It is a privilege to address you for the first time as CEO of Tivic. I'm honored to lead the company at this transformative juncture. My focus is clear and resolute evolving Tivic into a high-impact immunotherapy company dedicated to saving lives, advancing critical therapies to patients and delivering significant long-term value to our shareholders." Handley highlighted the company’s full pivot into immunotherapy, now anchored by the TLR5 platform, with lead candidates Entolimod and Entolasta at the center of this new strategic direction.
* Handley stated the company completed its acquisition of in-house manufacturing capabilities and launched Velocity Bioworks, which is expected to offer both cost efficiencies for Tivic and a new revenue stream as a contract manufacturing organization. "By internalizing our manufacturing, we have already achieved substantial reduction in development time lines and costs for Entolimod. Additionally, we have controlled our own supply chain and are poised to scale Entolimod as needed."
* The CEO described the discontinuation of all non-core businesses, including the ClearUP device and neuromodulation programs, allowing Tivic to focus exclusively on biotherapeutics: "By shedding these legacy assets, we have concentrated 100% of our resources on high-value biotherapeutic opportunities."
* Handley outlined a strategic focus on the oncology supportive care market, referencing its estimated value of nearly $15 billion and expected growth to $20 billion by the 2030s. He emphasized that Tivic is "aggressively moving Entolimod into large market clinical indications, beginning with neutropenia," and targeting physician-sponsored trials within the year.
* The CEO also pointed to active engagement with U.S. government agencies for potential biodefense contracts: "We are actively engaged with BARDA, NIAID and the Department of Water to secure non-dilutive government funding assistance in testing and development of Entolimod for ARS."
* Lisa Wolf, CFO, reported, "Operating expenses were $7.9 million compared to $4.5 million for the year ended December 31, 2024. The increase was primarily due to the introduction of the biopharma business in February 2025, when the company licensed certain biologics and increased our headcount and professional services to support the development of Entolimod."
* Wolf added, "At December 31, 2025, cash and cash equivalents totaled $12.6 million compared with $2 million at December 31, 2024. We also have $6 million of funds remaining in planned tranches of our preferred purchase agreement entered into in December 2025."

OUTLOOK

* Management indicated plans to initiate physician-sponsored trials for Entolimod as early as this year, providing proof of efficacy and forming the basis for future Phase IIb studies.
* Wolf stated, "We believe we're positioned to continue our progress towards GMP manufacturing validation for Entolimod and ramp operations of our CDMO with the intent to bring in third-party customers over the next year."
* Handley emphasized a dual market strategy: immediate national preparedness opportunities and long-term value in global oncology supportive care.

FINANCIAL RESULTS

* Wolf reported, "Loss from discontinued operations decreased from $1.2 million to $900,000 for the year ended December 31, 2025. Discontinued operations included all activities related to the consumer product business that Tivic exited in 2025."
* She detailed the financing for the Scorpius Holdings asset purchase with a $16.3 million convertible note and warrant for 4,553,213 shares.
* Wolf noted, "Subsequent to year-end, in February, we entered into a common stock purchase agreement whereby we have the right, but not the obligation to raise up to $50 million under certain conditions for approximately the next 2 years."

Q&A

* NOT_APPLICABLE: No analyst questions or Q&A were included in the provided transcript.

SENTIMENT ANALYSIS

* The absence of analyst questions precludes direct assessment of analyst sentiment.
* Management’s tone was confident and forward-looking, focusing on the company’s transformation, strategic focus, and new market opportunities. Handley’s remarks conveyed, "We are committed to executing our vision and look forward to providing further updates as we reach our upcoming milestones."
* Compared to the previous quarter, the sentiment remains positive, with added emphasis on execution following the completed transition and new leadership.

QUARTER-OVER-QUARTER COMPARISON

* The current quarter marks the first under CEO Michael Handley, reflecting a completed shift from consumer devices to a pure-play biopharmaceutical company focused on immunotherapy and manufacturing.
* Previous quarter discussions centered on the transition and initial licensing of Entolimod, while the current quarter details the full exit from legacy businesses, the launch of CDMO operations, and acquisition of in-house manufacturing.
* Key financial metrics show a substantial increase in cash reserves and operating expenses due to new business lines and acquisitions.
* Strategic focus has moved from planning and early execution to operationalization and scale-up, with management expressing heightened confidence in achieving near-term milestones.

RISKS AND CONCERNS

* Wolf highlighted ongoing finalization of certain accounting matters related to the $16.3 million debt instrument.
* The company faces risks inherent in advancing clinical development for Entolimod and scaling new CDMO operations.
* Management stated that the company’s ability to raise up to $50 million over the next two years offers flexibility, though there is no obligation to draw on these funds.
* The company has discontinued non-core programs to mitigate risk and concentrate resources on core biotherapeutic assets.

FINAL TAKEAWAY

Tivic Health Systems has completed a fundamental transformation, exiting legacy consumer device businesses and emerging as a focused immunotherapy company centered on the TLR5 platform. With Entolimod and Entolasta targeting large, high-value oncology supportive care and biodefense markets, in-house manufacturing through Velocity Bioworks, and a strengthened cash position, management expresses confidence in the company’s ability to deliver value through clinical development, government partnerships, and expansion into third-party manufacturing services.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/tivc/earnings/transcripts]

MORE ON TIVIC HEALTH SYSTEMS

* Tivic Health Systems, Inc. (TIVC) Q4 2025 Earnings Call Prepared Remarks Transcript [https://seekingalpha.com/article/4885927-tivic-health-systems-inc-tivc-q4-2025-earnings-call-prepared-remarks-transcript]
* Tivic Health Systems, Inc. (TIVC) Discusses Acquisition of Biomanufacturing Assets and Strategic Transformation Transcript [https://seekingalpha.com/article/4858947-tivic-health-systems-inc-tivc-discusses-acquisition-of-biomanufacturing-assets-and-strategic]
* Financial information for Tivic Health Systems [https://seekingalpha.com/symbol/TIVC/income-statement]